PGNY Progyny, Inc.
Services-Misc Health & Allied Services, NEC · Nasdaq · SEC CIK 1551306 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.5%
TTM net income YoY60.9%
TTM EPS YoY73.0%
Revenue 3-yr CAGR9.0%
Net income 3-yr CAGR20.5%
Margins
Gross margin24.9%
Operating margin9.4%
Net margin6.8%
FCF margin13.4%
EBITDA margin9.9%
Returns
ROE18.7%
ROA12.4%
ROIC (approx.)23.9%
Asset turnover1.82x
Leverage & solvency
Liabilities / assets38.7%
Debt / equity0.00x
Current ratio1.93x
Interest coverage—
Cash quality & payout
Operating cash flow / net income2.28x
Accruals ratio-15.8%
Payout ratio—
Capex / revenue2.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q42025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q42024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $341.25M | $350.51M | $328.50M | $318.40M | $313.35M | $332.87M | $324.04M | $298.43M |
| Cost of revenue | $257.51M | $261.21M | $245.43M | $241.52M | $240.51M | $253.90M | $248.24M | $235.00M |
| Gross profit | $83.74M | $89.30M | $83.07M | $76.88M | $72.83M | $78.97M | $75.80M | $63.43M |
| R&D expense | $3.10M | $3.30M | $2.80M | $3.10M | $2.60M | $2.30M | $1.50M | — |
| SG&A expense | $30.50M | $31.22M | $30.81M | $43.67M | $33.37M | $36.21M | $33.84M | $32.03M |
| Operating income | $35.18M | $40.00M | $35.38M | $15.22M | $21.53M | $24.36M | $24.17M | $15.79M |
| Pretax income | $36.42M | $41.14M | $36.88M | $17.85M | $23.96M | $27.08M | $26.54M | $17.66M |
| Income tax | $10.16M | $13.09M | $12.65M | $5.37M | $10.10M | $9.96M | $11.48M | $7.13M |
| Net income | $26.25M | $28.05M | $24.23M | $12.48M | $13.86M | $17.11M | $15.06M | $10.53M |
| EBITDA | $37.33M | $41.63M | $36.86M | $16.59M | $22.80M | $25.56M | $25.28M | $16.66M |
| EPS (basic) | 0.34 | 0.36 | 0.30 | 0.15 | 0.16 | 0.20 | 0.18 | 0.12 |
| EPS (diluted) | 0.32 | 0.34 | 0.29 | 0.14 | 0.15 | 0.19 | 0.17 | 0.12 |
| Weighted avg. shares (diluted) | 81.17M | 82.14M | 84.76M | 89.46M | 90.23M | 89.64M | 89.31M | 88.91M |
| Balance sheet | ||||||||
| Cash & equivalents | $116.82M | $152.63M | $131.61M | $112.24M | $133.98M | $132.51M | $109.24M | $162.31M |
| Short-term investments | $78.77M | $84.29M | $93.50M | $197.86M | $211.22M | $172.59M | $146.88M | $65.64M |
| Receivables | $249.18M | $257.48M | $263.61M | $220.29M | $252.50M | $271.85M | $299.74M | $235.32M |
| Current assets | $464.40M | $513.02M | $501.55M | $551.77M | $622.01M | $594.40M | $567.69M | $472.72M |
| PP&E, net | $50.25M | $41.99M | $35.71M | $29.93M | $24.74M | $19.94M | $15.74M | $12.38M |
| Goodwill | $19.83M | $19.85M | $19.88M | $19.98M | $19.96M | $19.96M | $19.65M | $15.53M |
| Intangibles | $5.53M | $5.75M | $5.97M | $6.22M | $6.43M | $6.64M | $6.75M | $1.30M |
| Total assets | $675.79M | $715.84M | $698.34M | $742.43M | $795.23M | $760.95M | $730.28M | $607.10M |
| Current liabilities | $240.04M | $240.08M | $235.74M | $202.39M | $210.49M | $220.42M | $237.13M | $168.63M |
| Total liabilities | $261.76M | $262.58M | $258.99M | $226.39M | $235.22M | $245.93M | $263.13M | $185.04M |
| Shareholders' equity | $414.03M | $453.26M | $439.34M | $516.04M | $560.00M | $515.02M | $467.16M | $422.06M |
| Shares outstanding | 74.72M | 77.39M | 78.27M | 83.37M | 86.15M | 85.93M | 85.67M | 85.31M |
| Cash flow statement | ||||||||
| Operating cash flow | $56.60M | $50.42M | $45.95M | $54.20M | $50.67M | $55.51M | $49.81M | $52.16M |
| Capital expenditure | $9.37M | $6.22M | $6.35M | $5.61M | $4.68M | $5.27M | $2.84M | $1.90M |
| Free cash flow | $47.24M | $44.21M | $39.60M | $48.59M | $45.99M | $50.24M | $46.97M | $50.27M |
| Investing cash flow | -$5.02M | $3.55M | $96.59M | $8.26M | -$42.74M | -$29.91M | -$94.61M | $74.99M |
| Financing cash flow | -$87.40M | -$32.89M | -$123.11M | -$88.26M | -$5.49M | -$2.33M | -$3.29M | -$56.33M |
| Depreciation & amortization | $2.15M | $1.62M | $1.48M | $1.37M | $1.27M | $1.21M | $1.11M | $868,000 |
| Stock-based compensation | $21.11M | $20.48M | $19.72M | $34.80M | $32.17M | $32.38M | $32.51M | $30.86M |
| Share buybacks | $82.78M | $30.02M | $118.61M | $81.66M | $0 | $0 | $0 | $55.10M |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.